3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Breast Neoplasms
4
Stomach Neoplasms
1
Squamous Intraepithelial Lesions
1
Smoldering Multiple Myeloma
1
Psychological Well-Being
1
Ovarian Neoplasms
1
Muscle Invasive Bladder Cancer (MIBC)
1
Multiple Myeloma
1
Motor Activity
1
Monoclonal Gammopathy of Undetermined Significance
1
Malnutrition
1
Lung Neoplasms
1
Limited Stage Small Cell Lung Cancer
1
Inflammation
1
Helicobacter Infections
1
Esophageal Neoplasms
1
Diarrhea
1
Colorectal Neoplasms
1
Breast Carcinoma In Situ
1
Interventions
Oxaliplatin
64
pembrolizumab
48
Fluorouracil
44
Capecitabine
38
Nivolumab
33
Leucovorin
32
Paclitaxel
28
Trastuzumab
19
Docetaxel
18
Cisplatin
18
S 1 (combination)
16
Bevacizumab
15
Ramucirumab
13
Irinotecan
13
Drug Therapy
13
tislelizumab
12
Cyclophosphamide
12
fludarabine
10
Carboplatin
10
Radiotherapy
9
Magnetic Resonance Spectroscopy
9
trastuzumab deruxtecan
8
sintilimab
8
Specimen Handling
8
Biopsy
8
atezolizumab
7
Surgical Procedures, Operative
7
Gemcitabine
7
zolbetuximab
6
durvalumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Probiotics
×
1 year
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled